These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 32915950)

  • 1. Activity of transgene-produced B-domain-deleted factor VIII in human plasma following AAV5 gene therapy.
    Rosen S; Tiefenbacher S; Robinson M; Huang M; Srimani J; Mackenzie D; Christianson T; Pasi KJ; Rangarajan S; Symington E; Giermasz A; Pierce GF; Kim B; Zoog SJ; Vettermann C
    Blood; 2020 Nov; 136(22):2524-2534. PubMed ID: 32915950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Phase Clinical Immunogenicity of Valoctocogene Roxaparvovec, an AAV5-Mediated Gene Therapy for Hemophilia A.
    Long BR; Veron P; Kuranda K; Hardet R; Mitchell N; Hayes GM; Wong WY; Lau K; Li M; Hock MB; Zoog SJ; Vettermann C; Mingozzi F; Schweighardt B
    Mol Ther; 2021 Feb; 29(2):597-610. PubMed ID: 33309883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical immunogenicity outcomes from GENEr8-1, a phase 3 study of valoctocogene roxaparvovec, an AAV5-vectored gene therapy for hemophilia A.
    Long BR; Robinson TM; Day JRS; Yu H; Lau K; Imtiaz U; Patton KS; de Hart G; Henshaw J; Agarwal S; Vettermann C; Zoog SJ; Gupta S
    Mol Ther; 2024 Jul; 32(7):2052-2063. PubMed ID: 38796703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia A.
    Pasi KJ; Rangarajan S; Mitchell N; Lester W; Symington E; Madan B; Laffan M; Russell CB; Li M; Pierce GF; Wong WY
    N Engl J Med; 2020 Jan; 382(1):29-40. PubMed ID: 31893514
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prednisolone Does Not Regulate Factor VIII Expression in Mice Receiving AAV5-hFVIII-SQ: Valoctocogene Roxaparvovec.
    Zhang L; Handyside B; Murphy R; Sihn CR; Xie L; Vitelli C; Harmon D; Sisó S; Liu S; Bullens S; Bunting S; Fong S
    Mol Ther Methods Clin Dev; 2020 Jun; 17():13-20. PubMed ID: 31890737
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interindividual variability in transgene mRNA and protein production following adeno-associated virus gene therapy for hemophilia A.
    Fong S; Yates B; Sihn CR; Mattis AN; Mitchell N; Liu S; Russell CB; Kim B; Lawal A; Rangarajan S; Lester W; Bunting S; Pierce GF; Pasi KJ; Wong WY
    Nat Med; 2022 Apr; 28(4):789-797. PubMed ID: 35411075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Effectiveness of Valoctocogene Roxaparvovec and Prophylactic Factor VIII Replacement in Severe Hemophilia A.
    Oldenburg J; Chambost H; Liu H; Hawes C; You X; Yang X; Newman V; Robinson TM; Hatswell AJ; Hinds D; Santos S; Ozelo M
    Adv Ther; 2024 Jun; 41(6):2267-2281. PubMed ID: 38616241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis.
    Astermark J; Buckner TW; Frenzel L; Hatswell AJ; You X; Liu H; Goodman E; Santos S; Hawes C; Hinds D; Klamroth R
    Haemophilia; 2023 Jul; 29(4):1087-1094. PubMed ID: 37347645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.
    Ozelo MC; Mahlangu J; Pasi KJ; Giermasz A; Leavitt AD; Laffan M; Symington E; Quon DV; Wang JD; Peerlinck K; Pipe SW; Madan B; Key NS; Pierce GF; O'Mahony B; Kaczmarek R; Henshaw J; Lawal A; Jayaram K; Huang M; Yang X; Wong WY; Kim B;
    N Engl J Med; 2022 Mar; 386(11):1013-1025. PubMed ID: 35294811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of ER Stress by an AAV5 BDD FVIII Construct Is Dependent on the Strength of the Hepatic-Specific Promoter.
    Fong S; Handyside B; Sihn CR; Liu S; Zhang L; Xie L; Murphy R; Galicia N; Yates B; Minto WC; Vitelli C; Harmon D; Ru Y; Yu GK; Escher C; Vowinckel J; Woloszynek J; Akeefe H; Mahimkar R; Bullens S; Bunting S
    Mol Ther Methods Clin Dev; 2020 Sep; 18():620-630. PubMed ID: 32775496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A.
    Pasi KJ; Laffan M; Rangarajan S; Robinson TM; Mitchell N; Lester W; Symington E; Madan B; Yang X; Kim B; Pierce GF; Wong WY
    Haemophilia; 2021 Nov; 27(6):947-956. PubMed ID: 34378280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. AAV5-Factor VIII Gene Transfer in Severe Hemophilia A.
    Rangarajan S; Walsh L; Lester W; Perry D; Madan B; Laffan M; Yu H; Vettermann C; Pierce GF; Wong WY; Pasi KJ
    N Engl J Med; 2017 Dec; 377(26):2519-2530. PubMed ID: 29224506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The canine factor VIII 3'-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo.
    Notley C; Killoran A; Cameron C; Wynd K; Hough C; Lillicrap D
    Hum Gene Ther; 2002 Sep; 13(13):1583-93. PubMed ID: 12228013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.
    Madan B; Ozelo MC; Raheja P; Symington E; Quon DV; Leavitt AD; Pipe SW; Lowe G; Kenet G; Reding MT; Mason J; Wang M; von Drygalski A; Klamroth R; Shapiro S; Chambost H; Dunn AL; Oldenburg J; Chou SC; Peyvandi F; Millar CM; Osmond D; Yu H; Dashiell-Aje E; Robinson TM; Mahlangu J
    J Thromb Haemost; 2024 Jul; 22(7):1880-1893. PubMed ID: 38614387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.
    Mahlangu J; Kaczmarek R; von Drygalski A; Shapiro S; Chou SC; Ozelo MC; Kenet G; Peyvandi F; Wang M; Madan B; Key NS; Laffan M; Dunn AL; Mason J; Quon DV; Symington E; Leavitt AD; Oldenburg J; Chambost H; Reding MT; Jayaram K; Yu H; Mahajan R; Chavele KM; Reddy DB; Henshaw J; Robinson TM; Wong WY; Pipe SW;
    N Engl J Med; 2023 Feb; 388(8):694-705. PubMed ID: 36812433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A.
    Dooriss KL; Denning G; Gangadharan B; Javazon EH; McCarty DA; Spencer HT; Doering CB
    Hum Gene Ther; 2009 May; 20(5):465-78. PubMed ID: 19222367
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring the Potential Feasibility of Intra-Articular Adeno-Associated Virus-Mediated Gene Therapy for Hemophilia Arthropathy.
    Zhang F; Yan X; Li M; Hua B; Xiao X; Monahan PE; Sun J
    Hum Gene Ther; 2020 Apr; 31(7-8):448-458. PubMed ID: 32079420
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.
    Sun J; Hua B; Chen X; Samulski RJ; Li C
    Hum Gene Ther; 2017 Aug; 28(8):654-666. PubMed ID: 28478688
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of therapeutic levels of factor VIII in hemophilia A mice using a novel adeno/adeno-associated hybrid virus.
    Gnatenko DV; Wu Y; Jesty J; Damon AL; Hearing P; Bahou WF
    Thromb Haemost; 2004 Aug; 92(2):317-27. PubMed ID: 15269828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype.
    Sarkar R; Xiao W; Kazazian HH
    J Thromb Haemost; 2003 Feb; 1(2):220-6. PubMed ID: 12871492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.